CHAPTER 1 - MARKET SUMMARY
Market Overview
The Global Neurovascular Devices Market serves acute ischemic stroke, cerebral aneurysm, stenosis, arteriovenous malformation and related endovascular interventions. Global stroke incidence reached approximately 11.9 Mn new cases in 2021, while ischemic stroke represented 65.3% of cases. Large-vessel occlusion is estimated at roughly 10%-20% of ischemic strokes, creating a substantial procedure pool beyond currently treated volumes.
Geographic demand is concentrated in developed neurointerventional systems, but the largest incremental procedure opportunity lies in underpenetrated Asian markets. China performed 81,865 mechanical thrombectomy procedures in 2023, up 16.2% year on year, yet its mechanical thrombectomy rate was only 2.56%. The combination of high stroke burden and low treatment penetration supports sustained investment in stroke centers, referral networks and neurointerventional training.
Market Value
USD 4,700 Mn
2025
Dominant Region
North America
2025
Dominant Segment
Embolization Devices, Product Type
2025
Total Number of Players
~53
Future Outlook
The Global Neurovascular Devices Market is projected to increase from USD 4,700 Mn in 2025 to approximately USD 8,162 Mn by 2032, representing an 8.2% value CAGR. Procedure-equivalent volume is projected to rise faster, from approximately 0.79 Mn to 1.492 Mn procedures, supported by thrombectomy access expansion, broader stroke-center certification and continued aneurysm treatment innovation. Because volume growth exceeds value growth, the market model incorporates gradual blended device-price erosion. The transition is particularly relevant in China and other emerging markets where public procurement and tender pricing can lower ASPs while simultaneously enabling higher procedural throughput.
The forecast therefore reflects two opposing forces: strong treatment-volume expansion and moderate pricing compression. The authoritative 2030 base case is USD 6,972 Mn, compared with an arithmetic-normalized bear scenario of USD 5,750 Mn and a bull scenario of USD 8,050 Mn. The bear case implies approximately 4.1% annual growth from the 2025 base, while the bull case implies approximately 11.4%. Premium flow-diversion and intrasaccular technologies support value realization in developed markets, whereas thrombectomy access expansion is expected to contribute the largest incremental procedure pool in Asia Pacific and other underpenetrated geographies.
8.2%
Forecast CAGR
USD 8,162 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2026-2032
Historical CAGR
12.6%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage this market analysis for investment, strategy and operational planning.
Investors
CAGR, concentration, margin resilience, M&A timing, scenario upside
Corporates
portfolio gaps, ASP pressure, channels, R&D, tender exposure
Government
stroke access, reimbursement, center capacity, procurement, local manufacturing
Operators
procedure throughput, device mix, training, inventory, referral conversion
Financial institutions
revenue visibility, consolidation, cash generation, regulatory risk, debt
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. The 2025 value is the authoritative triangulated base supplied for this report; historical values are scope-normalized benchmark estimates, while 2031-2032 extend the supplied 2030 model using the same value and volume growth framework.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance
Historical scope-normalized benchmarks indicate a 12.6% CAGR between 2020 and 2025. The strongest modeled annual expansion occurred in 2024 at 18.3%, reflecting greater thrombectomy penetration, broader use of flow diversion and recovery of elective neurointerventional procedure throughput. Procedure-equivalent volume rose from approximately 0.48 Mn in 2020 to 0.79 Mn in 2025. Blended device value moved from approximately USD 5,417 per procedure equivalent to USD 5,950, indicating that premium technology mix supported value growth before emerging-market procurement pressure became more material.
Forecast Market Outlook
From 2025 through 2032, value is projected to grow at 8.2% annually while procedure volume rises approximately 9.5% annually. The gap between these rates reflects declining blended device value, from approximately USD 5,950 per treated procedure in 2025 to USD 5,472 by 2032. The authoritative 2030 bear, base and bull values are USD 5,750 Mn, USD 6,972 Mn and USD 8,050 Mn respectively. Sanity-check arithmetic implies approximately 4.1%, 8.2% and 11.4% five-year CAGRs for those scenarios, correcting the originally stated bear-case growth rate.
CHAPTER 5 - Market Data
Market Breakdown
The Global Neurovascular Devices Market is transitioning toward higher procedure throughput but lower blended ASP growth. For executives and investors, the central issue is whether access-led volume expansion can outpace VBP, tender and distributor pricing pressure while premium aneurysm and thrombectomy technologies protect attractive device economics.
Year | Market Size (USD Mn) | YoY Growth (%) | Procedure Volume (Mn) | Blended Device Value (USD/Procedure) | Top-3 Share (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $2,600 Mn | +- | 0.480 | 5,417 | Forecast | |
| 2021 | $2,700 Mn | +3.9% | 0.510 | 5,294 | Forecast | |
| 2022 | $3,100 Mn | +14.8% | 0.560 | 5,536 | Forecast | |
| 2023 | $3,550 Mn | +14.5% | 0.630 | 5,635 | Forecast | |
| 2024 | $4,200 Mn | +18.3% | 0.720 | 5,833 | Forecast | |
| 2025 | $4,700 Mn | +11.9% | 0.790 | 5,950 | Forecast | |
| 2026 | $5,085 Mn | +8.2% | 0.865 | 5,879 | Forecast | |
| 2027 | $5,502 Mn | +8.2% | 0.947 | 5,809 | Forecast | |
| 2028 | $5,953 Mn | +8.2% | 1.037 | 5,741 | Forecast | |
| 2029 | $6,442 Mn | +8.2% | 1.136 | 5,673 | Forecast | |
| 2030 | $6,972 Mn | +8.2% | 1.244 | 5,606 | Forecast | |
| 2031 | $7,544 Mn | +8.2% | 1.362 | 5,539 | Forecast | |
| 2032 | $8,162 Mn | +8.2% | 1.492 | 5,472 | Forecast |
Procedure Volume
0.79 Mn procedures, 2025, global. Treatment penetration, not stroke incidence alone, is the principal volume lever. China recorded 81,865 mechanical thrombectomies in 2023 with a 2.56% thrombectomy rate, demonstrating the magnitude of underpenetrated procedure capacity.
Blended Device Value
USD 5,950 per procedure, 2025, global. Device economics vary substantially by technique and product mix. A recent US analysis reported thrombectomy device-related costs spanning approximately USD 7,836 to USD 19,069 per case, supporting a wide ASP envelope across procedure configurations.
Top-3 Share
68.0%, 2024, global. Stryker, Medtronic and Terumo form the dominant concentration block. Penumbra's 2025 thrombectomy revenue increased 16.2% and embolization/access revenue increased 20.2%, illustrating how scaled challengers can continue gaining procedure exposure despite incumbent concentration.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, clinical demand, procurement pathways, treatment technology and regional access patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Geography
Product Type
Care Setting
End User
Disease Area
Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions provides insights into device economics, physician adoption, referral pathways, procurement structures and regional treatment penetration.
Product Type
Product architecture is the most commercially important segmentation dimension because individual procedures commonly require multiple devices and because technology category determines clinical use, pricing and competitive positioning. Embolization Devices remain the largest established product pool, while neurothrombectomy systems, flow diversion and intrasaccular devices support differentiated growth through improved treatment options and expanded procedural eligibility.
Geography
Geography is expected to deliver the fastest structural change because treatment access remains highly uneven. Asia Pacific combines substantial stroke burden with lower mechanical thrombectomy penetration, particularly across China, India and developing Southeast Asian systems. Stroke-center expansion, public reimbursement and physician training can therefore produce procedure growth faster than mature North American and Western European markets despite lower regional ASP realization.
CHAPTER 7 - Regional Analysis
Regional Analysis
North America remains the largest regional revenue pool due to mature neurointerventional infrastructure, favorable procedural reimbursement and high adoption of premium aneurysm and stroke devices. Asia Pacific presents the strongest volume-growth opportunity because stroke burden is high and thrombectomy access remains substantially below mature-market levels. Regional values below apply published 2025 revenue-share benchmarks to the report's locked global base.
Regional Ranking
1st, North America
North America 2025 Allocation
USD 2,049 Mn
Fastest-Growing Region
Asia Pacific, 11.0% model CAGR (2026-2032)
Regional Ranking
1st, North America
North America 2025 Allocation
USD 2,049 Mn
Fastest-Growing Region
Asia Pacific, 11.0% model CAGR (2026-2032)
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | North America | Europe | Asia Pacific | Latin America | Middle East and Africa |
|---|---|---|---|---|---|
| Market Size, 2025 (USD Mn) | 2,049 | 1,222 | 1,109 | 202 | 118 |
| CAGR, 2026-2032 (%) | 7.2% | 7.1% | 11.0% | 8.5% | 9.0% |
| Demand-Side KPI | High treatment and premium-device maturity | High neurointerventional utilization | Very high burden with underpenetrated EVT | Emerging treatment penetration | Emerging treatment penetration |
| Supply/Policy-Side KPI | Mature comprehensive stroke-center ecosystem | Mature access with MDR compliance transition | Rapid center expansion and tender procurement | Concentrated specialist-center access | Uneven specialist and referral infrastructure |
Market Position
North America represents the largest benchmark allocation at 43.6% of 2025 global revenue, corresponding to approximately USD 2,049 Mn on this report's scope-normalized base.
Growth Advantage
Asia Pacific is modeled at 11.0% CAGR through 2032 versus 7.2% in North America, supported by treatment-access catch-up and low current thrombectomy penetration in major stroke markets.
Competitive Strengths
North America benefits from mature premium-device adoption, while Asia Pacific's structural advantage is procedure headroom: China recorded 81,865 thrombectomies at only a 2.56% treatment rate in 2023.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Market Challenges & Market Opportunities
Comprehensive analysis of key factors shaping the Global Neurovascular Devices Market, including clinical demand, treatment-access expansion, pricing pressure, regulatory requirements and technology-led opportunities.
Growth Drivers
Expanding Stroke Burden and Treatable Patient Pool
- Ischemic stroke accounted for 65.3% of global strokes, creating the principal disease pool for mechanical thrombectomy and supporting devices.
- Large-vessel occlusion represents approximately 10%-20% of ischemic strokes; the report uses a 15% midpoint for addressable thrombectomy demand.
- Approximately 6.8 Mn people in the United States are estimated to live with unruptured brain aneurysms, supporting a substantial elective treatment funnel.
Mechanical Thrombectomy Access Gap Closure
- China's thrombectomy rate remained only 2.56% in 2023, leaving meaningful headroom for stroke-center certification, referral optimization and physician training.
- Fewer than 100,000 mechanical thrombectomies were performed globally in 2016, demonstrating how rapidly the addressable treatment infrastructure has expanded since early EVT adoption.
- Asia Pacific is identified as a leading growth geography in contemporary industry forecasts, supporting the report's 11.0% regional model CAGR.
Premium Neuroendovascular Technology Mix
- Embolization devices represented approximately 45.29% of the 2026 product mix in a broad neurovascular market benchmark, confirming their commercial importance.
- Penumbra reported 16.2% 2025 growth in thrombectomy revenue and 20.2% growth in embolization/access revenue, demonstrating continued procedure-driven innovation economics.
- Johnson & Johnson expanded its CEREGLIDE catheter portfolio across 2025-2026 launches, reinforcing ongoing investment in neurovascular access and aspiration systems.
Market Challenges
VBP and ASP Compression
- China's volume-based procurement framework creates direct pressure on mature coil, stent and catheter pricing, making manufacturing scale increasingly important to tender competitiveness.
- MicroPort NeuroScientific reported 3.8% revenue growth in 2025 while public disclosures highlighted domestic pricing pressure and stronger overseas momentum.
- Because modeled procedure volume grows about 9.5% annually versus 8.2% market value growth, suppliers require productivity gains and premium-device mix to preserve economics.
Treatment Access and Specialist Capacity Constraints
- China's 2.56% thrombectomy rate in 2023 demonstrates that disease prevalence alone does not convert into device demand without referral, imaging and specialist infrastructure.
- US thrombectomy-device costs have been reported at approximately USD 7,836-19,069 per case, creating affordability and reimbursement constraints in lower-resource systems.
- The report's 0.79 Mn treated-procedure estimate for 2025 remains far below the combined epidemiological candidate pool, making clinical access the key conversion bottleneck.
Regulatory Evidence and Compliance Burden
- FDA guidance addresses both preclinical and clinical study requirements for neurothrombectomy submissions, raising development complexity for new device entrants.
- European MDR transition deadlines extend to 2027 or 2028 for qualifying legacy devices, but manufacturers must meet updated regulatory and quality requirements.
- Multiple regional approval pathways increase the commercialization burden for smaller suppliers competing against diversified companies with global regulatory and clinical affairs infrastructure.
Market Opportunities
Asia Pacific EVT Scale-Up
- Monetizable upside comes from increasing thrombectomy procedure density in China, India and Southeast Asia, where stroke burden exceeds current specialist-center capacity.
- Manufacturers with local training, tender management and distributor scale are positioned to capture procedure growth even when per-device ASPs remain below US and European levels.
- Opportunity realization requires more thrombectomy-capable centers, faster LVO referral pathways and reimbursement coverage, particularly given China's 2.56% thrombectomy rate.
Premium Aneurysm Therapy Expansion
- Flow diverters and intrasaccular implants can support higher device value than commodity access products, strengthening the premium portion of the neurovascular profit pool.
- Specialist manufacturers, diversified medtech groups and high-volume aneurysm centers benefit from technology that expands options for complex wide-neck and bifurcation aneurysms.
- Clinical adoption depends on durable outcomes evidence, physician training and reimbursement support because neurovascular implant selection remains highly procedure and anatomy specific.
Consolidation-Enabled Platform Economics
- Consolidated platforms can spread R&D, clinical affairs and physician-training costs across larger revenue bases while combining thrombectomy, embolization and access portfolios.
- Stryker completed its approximately USD 4,900 Mn Inari Medical acquisition in 2025, broadening its vascular platform beyond legacy neurovascular exposure.
- Penumbra shareholders approved the Boston Scientific transaction in May 2026; completion remains subject to the transaction process and applicable closing conditions.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market is concentrated at the top but retains a specialized innovation tail. Approximately 53 competitors are estimated globally, including 4 large, 9 medium and roughly 40 smaller companies, while the leading three suppliers account for about 68% of the 2024 benchmark market.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Stryker | 33% est. | Portage, Michigan, United States | 1941 | Legacy neurovascular thrombectomy, flow diversion, embolization and access devices within the broader Vascular portfolio |
Medtronic | 18% est. | Dublin, Ireland | 1949 | Neurovascular thrombectomy, flow diversion, coils, stents, catheters and intrasaccular devices |
Terumo Corporation (MicroVention) | 17% est. | Tokyo, Japan | 1921 | Aneurysm embolization, flow diversion, access systems and neurovascular intervention devices |
Johnson & Johnson MedTech (CERENOVUS) | 9% est. | New Brunswick, New Jersey, United States | 1886 | Stroke thrombectomy, aspiration, access catheters and cerebral aneurysm intervention |
Penumbra, Inc. | 12% est. | Alameda, California, United States | 2004 | Aspiration thrombectomy, embolization and neurovascular access systems |
MicroPort NeuroScientific Corporation | 2% est. | Shanghai, China | 2012 | Neurovascular stents, coils, thrombectomy systems and access devices |
Balt Group | - | Montmorency, France | - | Neurovascular embolization, flow diversion and stroke intervention products |
ASAHI INTECC CO., LTD. | - | Aichi, Japan | 1976 | Neurovascular guidewires, microcatheters and procedural access technologies |
Rapid Medical Ltd. | - | Yokneam, Israel | - | Adjustable stent retrievers and neurovascular treatment systems |
Kaneka Corporation | - | Tokyo, Japan | 1949 | Neurovascular catheters, embolization support and interventional devices |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Analysis Covered
Market Share Analysis:
Compares supplier concentration using neurovascular-attributable revenue and procedure exposure.
Cross Comparison Matrix:
Benchmarks portfolio breadth, procedure scale, growth and margin resilience.
SWOT Analysis:
Evaluates technology, channel, regulatory, manufacturing and geographic competitive positions.
Pricing Strategy Analysis:
Assesses premium technology pricing against VBP and tender pressure.
Company Profiles:
Maps product focus, scale, ownership shifts and market participation.
CHAPTER 10 - REPORT TOC
Table of Contents
Phase 1Market Assessment Phase
11
Chapters
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Phase 2Go-To-Market Strategy Phase
15
Chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Mapped global neurovascular device revenue pools
- Reviewed stroke incidence and procedure access
- Benchmarked device ASPs and reimbursement
- Tracked regulatory approvals and procurement shifts
Primary Research
- Targeted neurointerventional physicians for interviews
- Targeted hospital sourcing leaders for interviews
- Targeted distributor executives for channel validation
- Targeted OEM leaders for portfolio validation
Validation and Triangulation
- 390 respondent target sample architecture
- Reconciled manufacturer revenues with procedures
- Cross-checked epidemiology against treated volumes
- Applied scenario and arithmetic sanity checks
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
- Uae Neurovascular Devices Market Report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
- Middle East neurovascular devices market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
- Indonesia Neurovascular Devices Market
- Vietnam Neurovascular Devices Market
- Thailand Neurovascular Devices Market
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- Germany Neurovascular Imaging Market
- Germany Endovascular Treatment Market
- Oman Stroke Rehabilitation Devices Market
- Mexico Cerebrovascular Intervention Market
- Brazil Neurological Diagnostic Devices Market
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals